Vericel Surges 5% as FDA Approval Boosts TRC Therapy Growth
Vericel’s stock climbs 4.96%, driven by FDA approval and new Phase 2 trials, outperforming peers and signaling strong 15‑20% annual growth potential.
2 minutes to read
VERICEL CORP
Vericel Corp (VCEL) Stock Snapshot: $42.97, 17.7M Volume, 2.1B Cap
Vericel Corp (VCEL) stock hits USD 42.97—track its 24‑hour gains, market cap, and biotech focus on stem cell tissue repair.
2 minutes to read